XOMA Royalty Corporation (XOMA) Covered Calls
Xoma Ltd is a biopharmaceutical company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases.
You can sell covered calls on XOMA Royalty Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XOMA (prices last updated Mon 10:45 AM ET):
| XOMA Royalty Corporation (XOMA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 25.85 | -0.45 | 25.55 | 26.01 | 3K | - | 0.3 |
| Covered Calls For XOMA Royalty Corporation (XOMA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Jan 17 | 25 | 0.10 | 25.91 | -3.5% | -67.2% | |
| Feb 21 | 25 | 0.35 | 25.66 | -2.6% | -17.6% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
XOMA Corp. discovers and develops innovative antibody-based therapeutics. It combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. It is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. The company's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could have a major effect on the treatment of diabetes. XOMA was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.
| Top 10 Open Interest For Jan 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | XLF covered calls | 1. | NMRA covered calls | |
| 2. | SLV covered calls | 7. | SPY covered calls | 2. | QUBT covered calls | |
| 3. | AAPL covered calls | 8. | TSLA covered calls | 3. | ACHR covered calls | |
| 4. | EEM covered calls | 9. | IWM covered calls | 4. | QBTS covered calls | |
| 5. | INTC covered calls | 10. | TLT covered calls | 5. | RUM covered calls | |
Want more examples? XOM Covered Calls | XONE Covered Calls
